UCB SA's latest marketcap:
As of 07/05/2025, UCB SA's market capitalization has reached $36.61 B. According to our data, UCB SA is the 603th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 36.61 B |
| Revenue (ttm) | 7.24 B |
| Net Income (ttm) | 1.25 B |
| Shares Out | 190.04 M |
| EPS (ttm) | 6.45 |
| Forward PE | 22.24 |
| Ex-Dividend Date | 04/25/2025 |
| Earnings Date | 07/31/2025 |
UCB SA's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | €36.61 B | -13.12% | 603 |
| 12/31/2024 | €36.46 B | 143.6% | 525 |
| 12/29/2023 | €14.97 B | 7.12% | 1064 |
| 12/30/2022 | €13.97 B | -26.25% | 1070 |
| 12/31/2021 | €18.95 B | 18.7% | 936 |
| 12/31/2020 | €15.96 B | 19.52% | 895 |
| 12/31/2019 | €13.36 B | -0.43% | 921 |
| 12/31/2018 | €13.41 B | 7.76% | 742 |
| 12/29/2017 | €12.45 B | 8.53% | 859 |
| 12/30/2016 | €11.47 B | -26.97% | 857 |
Company Profile
About UCB SA
UCB SA is a global biopharmaceutical company dedicated to developing innovative products and solutions for individuals suffering from neurology and immunology diseases. Headquartered in Brussels, Belgium, the company was established in 1925 and has since been a leader in its field.
Key Products and Solutions
- Cimzia – Treats inflammatory TNF-mediated diseases, including ankylosing spondylitis (AS), Crohn's disease, and rheumatoid arthritis.
- Vimpat, Keppra, and Briviact – Medications for epilepsy management.
- Neupro – Used for Parkinson’s disease and restless legs syndrome.
- Nayzilam – A nasal spray rescue treatment for epilepsy seizure clusters.
- Zyrtec and Xyzal – Allergy relief medications.
- Evenity – Designed for osteoporosis treatment in postmenopausal women.
- Bimzelx – Targets plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
- Fintepla – Treats Dravet/Lennox-Gastaut syndrome.
- RYSTIGGO and ZILBRYSQ – Solutions for generalized myasthenia gravis.
Pipeline and Development
UCB SA is actively involved in research and development, with ongoing projects including:
- Doxecitine/Doxribtimine – For TK2 deficiency disorder.
- Fenfluramine – Targeting CDKL5 deficiency disorder.
- Dapirolizumab Pegol – For systemic lupus erythematosus.
- STACCATO Alprazolam – Treats stereotypical prolonged seizures.
- Bepranemab – A potential treatment for Alzheimer’s disease.
- UCB0222 – Focused on Parkinson’s disease.
- UCB9741 and UCB1381 – For atopic dermatitis.
Additional Activities
Beyond its core pharmaceutical offerings, UCB SA also engages in contract manufacturing, further expanding its impact in the healthcare industry.
Frequently Asked Questions
-
What is UCB SA's (EBR-UCB) current market cap?As of 07/05/2025, UCB SA (including the parent company, if applicable) has an estimated market capitalization of $36.61 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does UCB SA (EBR-UCB) rank globally by market cap?UCB SA global market capitalization ranking is approximately 603 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.